Agree. A multiple of 5.7x on annualised recurring revenue is...

Agree. A multiple of 5.7x on annualised recurring revenue is ridiculous - esp for a growth stock like this one is.

They make a product which is essential to medicine both inpatient and outpatient, it has been endorsed thru multiple contracts and recontracting of clients. their Sth American base provides cheap OPEX relative to their competition, so I’d think theirs could be cheaper than existing offerings. The market is huge and so ripe for disruption as existing PACS systems are poorly liked by medical professionals I have spoken to.

I understand their Australian trial site is at Newcastle which is large and reputable as a hospital. They would have a cost advantage over existing players i would think. If they can convert that trial into a contract, well that would change the game.

And that’s ignoring their other verticals

About 170m shares churned since RTO so overhang almost done now. Will still be some trapped holders above too. Chart suggests resistance in 34-36 range, and anything above 38 would be a breakout. But its got a lot of work do before then i suspect.